Clinical trials
Intrahepatic Cholangiocarcinoma clinical trials
Below are recruiting intrahepatic cholangiocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04078230Recruiting
Extending lymph node removal during liver tumor surgery
This study looks at whether removing more lymph nodes while surgically removing an intrahepatic cholangiocarcinoma (bile duct cancer in the liver) improves outcomes. It may help by better checking and treating possible microscopic spread to lymph nodes.
Baltimore, MarylandAges 18–80 - NCT05678270RecruitingPhase 2
ICP-192 for FGFR2 fusion bile duct cancer that spread
This Phase 2 trial tests a medicine called ICP-192 in people with intrahepatic bile duct cancer that cannot be removed with surgery and has spread. It is for tumors that have an FGFR2 fusion/rearrangement, especially after prior chemotherapy stopped working.
Hefei, AnhuiAges 18 years+ - NCT06298968RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07780838RecruitingPhase 2
Combination therapy for advanced bile duct cancer with an FGFR2 change
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
Columbus, OhioAges 18 years+ - NCT07766187RecruitingPhase 2
Durvalumab and focused ultrasound for liver cancer after chemo
This trial tests combining two treatments: durvalumab (an immunotherapy drug) and histotripsy (a focused ultrasound that breaks down tumor tissue) for people with a type of liver cancer called intrahepatic cholangiocarcinoma. It aims to see if adding histotripsy after initial chemotherapy helps control the cancer better.
Madison, WisconsinAges 18 years+ - NCT06721286RecruitingPhase 2
Combining immunotherapy with chemotherapy before surgery for bile duct cancer
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07570849RecruitingPhase 2
Chidamide with chemotherapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07522476RecruitingPhase 2
VG2025 treatment for advanced bile duct cancer
This trial tests a new drug called VG2025 to treat advanced intrahepatic cholangiocarcinoma, a type of cancer that starts in the bile ducts inside the liver. The study aims to see if VG2025 is safe and effective at slowing or stopping this cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06664021RecruitingPhase 2
Tislelizumab and S-1 for recurrent high-risk bile duct cancer
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Fuyang, AnhuiAges 18–75 - NCT04954781RecruitingPhase 2
Chemo plus immunotherapy for advanced bile duct liver cancer
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04299581RecruitingPhase 2
Freezing treatment plus immunotherapy for advanced bile-duct cancer
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
ShanghaiAges 18 years+ - NCT07161869Recruiting
Lymph node check before surgery for bile duct cancer
This study looks at how well a special ultrasound-guided biopsy checks lymph nodes before surgery or liver transplant for bile duct cancer. The goal is to see if this method accurately shows whether the cancer has spread to nearby lymph nodes.
Rotterdam, South HollandAges 18 years+ - NCT07070700RecruitingPhase 2
Cryoablation with targeted therapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07063888RecruitingPhase 2
Chemoradiation after surgery for bile duct cancer
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
BeijingAges 18–80 - NCT06910722Recruiting
Liver transplant for bile duct cancer after treatment
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Before the transplant, you would receive radiation therapy (SIRT) and chemotherapy to shrink the tumor.
Clichy-sous-BoisAges 18–65 - NCT06888063RecruitingPhase 2
Chemo pump into the liver for bile duct cancer that can be surgically removed
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
Rotterdam, South HollandAges 18 years+ - NCT06140134Recruiting
Liver transplant for bile duct cancer that hasn't spread
This study tests if a liver transplant can help people with a type of bile duct cancer that can't be removed with surgery. You may join if the cancer has stayed stable or shrunk for at least 6 months with treatment.
Newark, New JerseyAges 18–89 - NCT06058663RecruitingPhase 1
Radiation and immunotherapy for advanced bile duct cancer
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
Jacksonville, FloridaAges 18 years+ - NCT04195503Enrolling by invitation
Liver transplant for stable advanced bile duct cancer
This trial looks at liver transplant for people with advanced intrahepatic cholangiocarcinoma (a bile duct cancer inside the liver) when the cancer is not safely removable and stays controlled. It may help some patients live longer and with better quality of life by replacing the diseased liver—if strict safety and disease-stability requirements are met.
Toronto, OntarioAges 18 years+ - NCT06098547Recruiting
Liver transplant for bile duct cancer that can't be removed
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. You must have had at least six months of chemotherapy and your cancer must be stable or smaller before you can be listed for a transplant.
PadovaAges 18–70 - NCT06746480RecruitingPhase 2
Study of VG161 for advanced bile duct cancer
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06956716RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for advanced bile duct cancer
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06858735RecruitingPhase 2
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Phase 2 trial evaluating systemic therapy ± liver-directed RT for advanced intrahepatic cholangiocarcinoma, with broad eligibility for patients who have received at least 4 cycles of gem/cis/durvalumab.
Houston, TexasAges 18 years+ - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Intrahepatic Cholangiocarcinoma trials by city
Studies with a site in or near these metro areas.
Intrahepatic Cholangiocarcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for intrahepatic cholangiocarcinoma?
- Yes. Clin2 currently lists 69 recruiting intrahepatic cholangiocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a intrahepatic cholangiocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a intrahepatic cholangiocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.